Latest Clinical Data of InnoCare’s Gunagratinib Presented at 2023 ASCO GI

We are committed to discovering, developing and commercializing best-in-class and/or first-in-class drugs for the treatment of cancer and autoimmune diseases. Led by a world-class management team of seasoned industry executives, we have built a fully integrated biopharmaceutical platform with strong in-house R&D capabilities, including drug target identification and verification, preclinical evaluation, clinical trial design and execution, drug manufacturing and quality control, and commercialization.
We focus on the discovery and development of innovative medicines to address significant unmet medical needs of diseases that are specially prevalence in Chinese population.
We have built a fully integrated biopharmaceutical platform that allows us to oversee all aspects of the drug development cycle. By having all functions in-house, we are able to improve operational efficiency and control quality every step of the way.

InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023 ASCO GI
InnoCare Announces Approval of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
